The Effect of Vitamin D3 Alone and Mixed With IFN-γ on Tachyzoites of Toxoplasma gondii (RH Strain) Proliferation and Nitric Oxide (NO) Production in Infected Macrophages of BALB/C Mice
,
Abstract
Introduction: Toxoplasma gondii is an obligatory interacelullar parasite that infects nucleated cells in its intermediate hosts. The aim of the present study was to determine the effect of vitamin D3 on the multiplication of T. gondii in peritoneal macrophage of Balb/c mice and nitric oxide production by macrophages.
Methods: According to usage of vitamin D3 (one dose or seven doses) and INFγ in vitro and in vivo, this study was divided into four experiments. In all experiments, the macrophages were collected from peritoneum and cultured in RPMI-1640. Then the supernatants were collected after 24 h and their nitric oxide was measure. After 96 h, the macrophages were collected and stained and the number of tachyzoites was measured.
Results: The first experiment (the mice were infected with tachyzoites and after 2 h, got one dosevitamin D3 intraperitonealy) showed the best results. The mean of tachyzoites per macrophages was 2.37, and mean ± SD of nitric oxide was 187.8 ± 9.
Discussion: High-level production of nitric oxide may be related to the only one injection of vitamin D3. The injection in long time might suppress the immune system.
Remington JS, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant. J S Remington JOW B Klein, ed. Saunders, Philadelphia, 1983.
McCabe R, Remington JS. Toxoplasmosis: the time has come. N Engl J Med. 1988; 313:318.
Luft BJ, Remington JS. AIDS commentary: toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992; 15:211.
Israelski DM, Remington JS. Toxoplasmosis in patients with cancer. Clin Infect Dis. 1993;17 ( l):S423.
Adams LB, Hibbs JB, Taintor RR, Krahenbuhl JL. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol. 1990; 144: 2725–2729.
Yap GS, Sher A. Effector cells of both non-hemopoietic and hemopoietic origin are required for interferon (IFN)-g- and tumour necrosis factor (TNF)-a-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J Exp Med. 1999; 189: 1083–1091.
Roberts F, Roberts CW, Ferguson DJ, McLeod R. Inhibtion of nitric oxide production exacerbates chronic ocular toxoplasmosis. Parasite Immunol. 2000; 22:1–5.
Schlu¨ ter D, Deckert-Schlu¨ ter M, Lorenz E, Meyer T, Ro¨llinghoff M, Bogdan C. Inhibition of inducible nitric oxide synthase exacerbates chronic cerebral toxoplasmosis in Toxoplasma gondiisusceptible C57BL/6 mice but does not reactivate the latent disease in T. gondiiresistant BALB/c mice. J Immunol. 1999; 162:3512–3518.
DeLuca HF, Schnoes HM. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem. 1976; 52:411–439.
Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 1995; 53(1-6):599–602.
Manolagas SC, Provvedini DM, Tsoukas CD. Interactions of 1,25-dihydroxyvita min D3 and the immune system. Deol Cell Endocrinol. 1985; 43:113–122.
Yu XP, Mocharla H, Hustmyer FG, Manolagas SC. Vitamin D receptor expression in human lymphocytes. Signal requirements and characterization by western blots and DNA sequencing. J Biol Chem. 1991; 266:7588–7595.
Manolagas SC, Provvedini DM, Murray EJ, Tsoukas CD, Deftos LJ. The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Lab Clin Med. 1986; 63(2):394–400.
Biyoudi-Vouenze R, Cadrand J, Valeyre D, Milleron B, Hance A, Soler P. Expression of 1,25(OH)2D3 receptors on alveolar lymphocytes from patients with pulmonary granulomatous diseases. Am Rev Respir Dis. 1991; 143:1376–1380.
Nakajima S, Yamada K, Yamamoto T, Okada S, Tanaka H, Seino Y. IL 3 and IL 6 do not induce bone resorption in vitro. Bone Miner. 1990; 10:201–209.
Manolagas SC, Provvedini DM, Murray EJ, Tsoukas CD, Deftos LJ. .Association between the expression of the c-myc oncogene mRNA and the expression of the receptor protein for 1,25- dihydroxyvitamin D3.J Clin Endocrinol Metab. 1986; 63:394–400.
Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science. 1984; 224:1438–1441.
Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991; 87:1103–1107.
Cantorna MT, Hayes CI, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci. USA. 1996; 93:7861–7864.
Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF-ß1 and IL-4. J Immunol. 1998; 160:5314-5319.
Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25- dihydroxyvitamin D3, KH1060. Endocrinology. 1995; 136: 866–872.
Hullett DA, Cantorna MT, Redaelli C, Humpal-Winter J, Hayes CE, Sollinger HW, DeLuca HF. Prolongation ofallograft survival by 1, 25-dihydroxyvitamin D3. Transplantation. 1998; 66:824–828.
DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J. 1988; 2(3):224–236.
Darwish HM, DeLuca HF. Vitamin Dregulated gene expression. Crit. Rev. Eukaryotic Gene Expression. 1993; 3:89–116.
Zanello LP, Norman AW. Rapid modulation of osteoblast ion channel responses by 1_, 25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. PNAS. February 10, 2004; 101( 6):1589–1594.
Rokett KA, Brookes R, Udalove I. 1,25- Dihydroxy vitamin D3 induces nitric oxide syntheses and suppresses growth of Mycobacterium tuberculosis in a human macrophage-link cell line. J Inf Immunity. 1998; 66:5314-5321. 27. Prabhu Anand S, Selvaraj P, Narayanan PR. Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-c and TNF-a positive T cell subsets in pulmonary tuberculosis. Cytokine. 2008; 43:26-33.
Seabra SH, DeSouza W, DaMatta RA. Toxoplasma gondii partially inhibits nitric oxide production of activated murine macrophage. Exp Parasitol. 2002; 100(1):62-70.
Schwalfenberg G. Not enough vitamin D for Canadians. Can Fam Physician. 2007; 53:841-854.
Davies PDO, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax. 1985; 40:187-190.
De la Torre MS, Torres C, Nieto G, Vergara S, Carrero AS, Macia J, Pineda JA, Caruz A, Fibla J. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. J Infect Dis. 2008; 197:405-410.
Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000; 374, 334–338.
Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trend Mol Med. 2002; 8:174–179.
Casteels K, Bouillon R, Waer M, Mathieu C. Immunomodulatory effects of 1,25(OH)2D3. Curr Opin Nephrol Hy. 1995; 4:313–318.
Bouillon R, Verstuyf AM, Verlinden L, Branisteanu D, Mathieu C, Van-Baelen H. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol. 1995; 50:577–583.
Verstuyf A, Segaert S, Verlinden L, Bouillon R, Mathieu C. Recent developments in the use of vitamin D analogues. Expert Opin Inv Drug. 2000; 9:443–455.
Ghaffarifar F, Dalimi Asl A, Sharifi Z, Ghasemi S, Solhjoo K, Roodbar Mohammadi S. The Effect of Betamethasone and IFN-γ on Replication of Toxoplasma gondii (RH Strain) and NitricOxide Production in HeLa Cell Culture. Iran J Allergy Asthm. 2006; 5(2): 75-78.
| Files | ||
| Issue | Vol 5 No 3 (2010) | |
| Section | Articles | |
| Keywords | ||
| Toxoplasma gondii Vitamin D3 Nitric Oxide IFN-γ Macrophages Mice | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
